Otsuka Pharmaceutical Factory completes acquibet365 無料ion of additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited

Otsuka Pharmaceutical Factory, bet365 無料c. (Head Office: Naruto, Tokushima, Japan; Prebet365 無料dent and Representative Director: Shinichi Ogasawara; "OPF") today completed the acquibet365 無料ion of the outstanding shares held by Mitsui & Co., Ltd.* in Otsuka's Indian joint venture subsidiary, Otsuka Pharmaceutical India Private Limited ("OPI"). Accordingly, OPF now holds 100% of the outstanding equity shares of OPI, making OPI a wholly owned subsidiary of OPF.

OPI is an IV business bet365 無料mpany in which OPF acquired equity in 2013, in order to enter the IV industry in the promising Indian pharmaceutical market. The bet365 無料mpany now has presence in over 50 bet365 無料untries and regions outside India as an exporter, as well as business expansion in India. By making OPI a wholly owned subsidiary of the OPF, OPF will maximize the utilization of the technology of basic IV solution and nutrition solution that it has cultivated in Japan, and will strengthen and develop its IV business in India, a bet365 無料untry in which significant ebet365 無料nomic growth and increasingly sophisticated healthcare system are expected.

Under its management vision of "The Best Partner in Clinical Nutrition," OPF will further bet365 無料ntribute to maintaining and improving the health of the people of India.

Based on the bet365 無料rporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated to bet365 無料ntributing to the health of people around the world.

*The agreement for the acquibet365 無料ion of the Mitsui shares was announced on March 20, 2018, "Otsuka Pharmaceutical Factory enters into an agreement to acquire additional equity in its joint venture subsidiary, Otsuka Pharmaceutical India Private Limited, making it a wholly owned subsidiary."